Movement Alert｜Abbott Laboratories Falls 3.5% in Regular Trading, Medical Device Sector Under Broad Pressure Ahead of Q2 Earnings

Market Focus07-14 22:11

On July 14, Abbott Laboratories fell 3.5% in regular trading, trading at $89.7/share, with turnover of $129 million. The decline coincided with broad-based weakness across the Health Care Equipment sector and rising risk-aversion sentiment ahead of the company's Q2 earnings release scheduled for July 16 pre-market.

The medical device sector experienced significant selling pressure, with peers Stryker down 5.67%, GE Healthcare down 5.73%, Intuitive Surgical down 3.9%, Medtronic down 3.76%, and Boston Scientific down 3.67%. Abbott has been under sustained pressure since April, when it lowered full-year adjusted EPS guidance to $5.38-$5.58 following Q1 results that were weighed down by international tender renewal delays impacting its continuous glucose monitoring business and short-term earnings dilution from the approximately $21 billion Exact Sciences acquisition. Multiple brokerages subsequently cut price targets, including Citi to $108, Oppenheimer to $115, and Daiwa downgrading the stock to Neutral with a $92 target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193668472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193668472","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abbott Laboratories Falls 3.5% in Regular Trading, Medical Device Sector Under Broad Pressure Ahead of Q2 Earnings","media":"Market Focus","content":"<p><p>On July 14, Abbott Laboratories fell 3.5% in regular trading, trading at $89.7/share, with turnover of $129 million. The decline coincided with broad-based weakness across the Health Care Equipment sector and rising risk-aversion sentiment ahead of the company's Q2 earnings release scheduled for July 16 pre-market.</p><p>The medical device sector experienced significant selling pressure, with peers Stryker down 5.67%, GE Healthcare down 5.73%, Intuitive Surgical down 3.9%, Medtronic down 3.76%, and Boston Scientific down 3.67%. Abbott has been under sustained pressure since April, when it lowered full-year adjusted EPS guidance to $5.38-$5.58 following Q1 results that were weighed down by international tender renewal delays impacting its continuous glucose monitoring business and short-term earnings dilution from the approximately $21 billion Exact Sciences acquisition. Multiple brokerages subsequently cut price targets, including Citi to $108, Oppenheimer to $115, and Daiwa downgrading the stock to Neutral with a $92 target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abbott Laboratories Falls 3.5% in Regular Trading, Medical Device Sector Under Broad Pressure Ahead of Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abbott Laboratories Falls 3.5% in Regular Trading, Medical Device Sector Under Broad Pressure Ahead of Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, Abbott Laboratories fell 3.5% in regular trading, trading at $89.7/share, with turnover of $129 million. The decline coincided with broad-based weakness across the Health Care Equipment sector and rising risk-aversion sentiment ahead of the company's Q2 earnings release scheduled for July 16 pre-market.</p><p>The medical device sector experienced significant selling pressure, with peers Stryker down 5.67%, GE Healthcare down 5.73%, Intuitive Surgical down 3.9%, Medtronic down 3.76%, and Boston Scientific down 3.67%. Abbott has been under sustained pressure since April, when it lowered full-year adjusted EPS guidance to $5.38-$5.58 following Q1 results that were weighed down by international tender renewal delays impacting its continuous glucose monitoring business and short-term earnings dilution from the approximately $21 billion Exact Sciences acquisition. Multiple brokerages subsequently cut price targets, including Citi to $108, Oppenheimer to $115, and Daiwa downgrading the stock to Neutral with a $92 target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1193668472","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193668472","pubTimestamp":1784038290,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, Abbott Laboratories fell 3.5% in regular trading, trading at $89.7/share, with turnover of $129 million. The decline coincided with broad-based weakness across the Health Care Equipment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"走势警报|雅培制药常规交易下跌 3.5%，医疗器械行业在第二季度财报公布前面临广泛压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"On July 14, Abbott Laboratories fell 3.5% in regular trading, trading at $89.7/share, with turnover of $129 million. The decline coincided with broad-based weakness across the Health Care Equipment sector and rising risk-aversion sentiment ahead of the company's Q2 earnings release scheduled for July 16 pre-market.The medical device sector experienced significant selling pressure, with peers Stryker down 5.67%, GE Healthcare down 5.73%, Intuitive Surgical down 3.9%, Medtronic down 3.76%, and Boston Scientific down 3.67%. Abbott has been under sustained pressure since April, when it lowered full-year adjusted EPS guidance to $5.38-$5.58 following Q1 results that were weighed down by international tender renewal delays impacting its continuous glucose monitoring business and short-term earnings dilution from the approximately $21 billion Exact Sciences acquisition. Multiple brokerages subsequently cut price targets, including Citi to $108, Oppenheimer to $115, and Daiwa downgrading the stock to Neutral with a $92 target.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193668472","isCrawlerRequest":true}